- Home
- PCN vs PACB Comparison
PCN vs PACB Comparison
Compare PCN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCN | PACB |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.4M | 696.3M |
| IPO Year | 2001 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PCN | PACB |
|---|---|---|
| Price | $10.62 | $1.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $2.78 |
| AVG Volume (30 Days) | 453.3K | ★ 12.3M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $10.44 | $1.07 |
| 52 Week High | $12.90 | $3.44 |
Technical Indicators
Market Signals| Indicator | PCN | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 41.59 |
| Support Level | $10.49 | $1.27 |
| Resistance Level | $11.98 | $3.07 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 6.24 | 6.72 |
Price Performance
Historical ComparisonAbout PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.